Mersana Therapeutics’ (MRSN) “Outperform” Rating Reaffirmed at Wedbush
Wedbush reaffirmed their outperform rating on shares of Mersana Therapeutics (NASDAQ:MRSN – Free Report) in a research report report published on Monday morning,RTT News reports. They currently have a $4.00 price objective on the stock. MRSN has been the topic of a number of other research reports. William Blair initiated coverage on Mersana Therapeutics in […]
Wedbush reaffirmed their outperform rating on shares of Mersana Therapeutics (NASDAQ:MRSN – Free Report) in a research report report published on Monday morning,RTT News reports. They currently have a $4.00 price objective on the stock. MRSN has been the topic of a number of other research reports. William Blair initiated coverage on Mersana Therapeutics in […]
